Every material Form 8-K JUPITER NEUROSCIENCES, INC. has filed with the SEC since August 24, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Nasdaq staff determined to delist Jupiter Neurosciences' common stock from the Nasdaq Capital Market after the company did not regain compliance with the $35,000,000 minimum market value of listed securities by August 25, 2026. The company intends to appeal to the Nasdaq Hearings Panel and expects the hearing request to stay further action, but it cannot assure that the appeal will succeed. Separately, the company regained compliance with the $1.00 minimum bid price requirement, though the delisting threat remains.
Nasdaq notice received August 27, 2026 states the Staff determined to delist the common stock from The Nasdaq Capital Market.
Market value of listed securities was below the $35,000,000 minimum; the compliance deadline was August 25, 2026.
Company intends to request a hearing before the Nasdaq Hearings Panel and expects this to stay further action; success is not assured.
Closing bid price was at least $1.00 for 10 consecutive business days, August 13 through August 26, 2026, and the bid price matter is closed.
On August 26, 2026, Jupiter Neurosciences' chairman and CEO, president and COO, chief scientific officer, and chief administrative officer irrevocably forgave $875,315 of accrued, unpaid compensation owed to them by the company. The filing says the forgiveness was gratuitous, with no equity issued and no cash or other consideration paid, so the change removes liabilities from the balance sheet without a cash outlay.
Total forgiven: $875,315 of accrued salaries reflected as liabilities on the balance sheet
Christer Rosén (Chairman and CEO and Director) forgave $356,024; Marshall Hayward, Ph.D. (Chief Scientific Officer and Director) forgave $287,075
Alison Silva (President, COO and Director) forgave $81,431; Alexander Rosén (Chief Administrative Officer) forgave $150,785
Effective August 26, 2026; the company issued no equity or cash in exchange, and each agreement includes a general release of related claims
Jupiter Neurosciences sold 307,692 shares at $6.50 each in a registered direct offering that closed August 24, 2026, for gross proceeds of about $2.0 million before fees and expenses. The company believes the sale brings its stockholders' equity above the $2.5 million Nasdaq continued-listing requirement, but it is still waiting for Nasdaq's formal confirmation, and its shares may face delisting if compliance is not shown at its next periodic report.
Shares issued: 307,692 common shares at $6.50 each, under an agreement dated August 21, 2026
Gross proceeds: approximately $2.0 million before placement agent fees and offering expenses, closed August 24, 2026
Nasdaq stockholders' equity requirement: $2.5 million; company awaiting formal determination of compliance
Delisting risk remains if compliance is not evidenced at the next periodic report
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every JUPITER NEUROSCIENCES, INC. filing is on SEC EDGAR ↗. 8-K briefs of other companies →